12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RTS: Additional Phase III data

Data from the per protocol (PP) population of 6,003 infants aged 6-12 weeks who received all 3 doses of RTS,S in a double-blind, African Phase III trial showed that the vaccine significantly reduced the incidence of clinical malaria, a co-primary endpoint, over a 12-month period following vaccination by 31.3% compared to the non-malaria comparator vaccine group (p<0.001). In the PP population, the vaccine also significantly reduced the incidence of severe malaria, a co-primary endpoint, over a 12-month period following vaccination by 36.6% compared to the non-malaria comparator vaccine group (p=0.02). In the intent-to-treat (ITT) population (n=6,537), the vaccine reduced...

Read the full 471 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >